ReviewNature reviews. Urology2015
Radiotherapy for high-risk prostate cancer.
Review in Nature reviews. Urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Efficacy and Toxicity of Whole Pelvic Radiotherapy Versus Prostate-Only Radiotherapy in Localized Prostate Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2019Trial
- Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.International journal of radiation oncology, biology, physics · 2017Trial
- Dosimetric benefits of half-field arc in prostate cancer treatment.Physical and engineering sciences in medicine · 2026Article
- PSMA PET-directed radiotherapy for prostate cancer: From precision planning to future innovations.View (Beijing, China) · 2026Article
- PTEN Mutations Associated with Increased Recurrence and Decreased Survival in Patients with Prostate Cancer Spinal Metastasis.Current oncology (Toronto, Ont.) · 2025Article
- PIM kinase inhibition counters resistance to radiotherapy and chemotherapy in human prostate cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025Article
- Changes in the gut microbial profile during long-term androgen deprivation therapy for prostate cancer.Prostate cancer and prostatic diseases · 2024Article
- Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.Scientific reports · 2021Article
- Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review.Frontiers in oncology · 2021Review
- Low-dose ionizing irradiation triggers apoptosis of undifferentiated spermatogoniaTranslational andrology and urology · 2019Article
- Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.PloS one · 2019Article
- Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment.Nature communications · 2017Article
- The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer.Current oncology reports · 2015Review
- Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.Experimental hematology & oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of radiation treatment and long-term androgen deprivation therapy (ADT) has been shown in multiple clinical trials to prolong overall survival in men with high-risk prostate cancer compared with either treatment alone. New radiation technologies enable the safe delivery of high radiation doses that improve cancer control compared with lower radiation doses. Based on the results of multiple randomized trials, clinical practice guidelines for high-risk prostate cancer recommend total radiation doses of at least 75.6 Gy, with long-term (2-3 years) ADT. Ongoing research into hypofractionated radiation treatment, whole-pelvic radiation, and combinations of radiation with novel hormonal agents could further improve cancer control and survival outcomes for patients with high-risk prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.